. . . . . "4.3\tKontraindikace"@cs . . . . . "T\u011B\u017Ek\u00E9 a neo\u010Dek\u00E1van\u00E9 reakce na l\u00E9\u010Dbu fluoropyrimidiny v anamn\u00E9ze. \nHypersenzitivita na kapecitabin nebo na kteroukoli pomocnou l\u00E1tku uvedenou v\u00A0bod\u011B 6.1 nebo na fluorouracil. \nU pacient\u016F se zn\u00E1m\u00FDm deficitem dihydropyrimidindehydrogen\u00E1zy (DPD). \nV pr\u016Fb\u011Bhu t\u011Bhotenstv\u00ED a kojen\u00ED. \nU pacient\u016F s t\u011B\u017Ekou leukopeni\u00ED, neutropeni\u00ED nebo trombocytopeni\u00ED. \nU pacient\u016F s t\u011B\u017Ek\u00FDm jatern\u00EDm po\u0161kozen\u00EDm. \nU pacient\u016F s t\u011B\u017Ek\u00FDm ren\u00E1ln\u00EDm po\u0161kozen\u00EDm (clearance kreatininu m\u00E9n\u011B ne\u017E 30 ml/min). \nL\u00E9\u010Dba sorivudinem nebo chemicky p\u0159\u00EDbuzn\u00FDmi l\u00E1tkami, nap\u0159. brivudinem (viz bod 4.5). \nP\u0159i existenci kontraindikace pro pou\u017Eit\u00ED n\u011Bkter\u00E9ho p\u0159\u00EDpravku v kombinovan\u00E9m re\u017Eimu nelze p\u0159\u00EDslu\u0161n\u00FD p\u0159\u00EDpravek pou\u017E\u00EDt.\n"@cs . . "004.003" .